T. Rowe Price reports 0.1% Avidity stake

T. Rowe Price Associates, Inc. filed Amendment No. 8 to a Schedule 13G reporting beneficial ownership of 142,888 shares of Avidity Biosciences, Inc. common stock, representing 0.1% of the class as of 12/31/2025.

Rhea-AI Filing Summary

T. Rowe Price Associates, Inc. filed Amendment No. 8 to a Schedule 13G reporting beneficial ownership of 142,888 shares of Avidity Biosciences, Inc. common stock, representing 0.1% of the class as of 12/31/2025.

The firm reports sole voting power over 140,624 shares and sole dispositive power over 142,888 shares, with no shared voting or dispositive power. It states the shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Avidity Biosciences, and that its ownership is 5 percent or less of the outstanding common stock.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What stake does T. Rowe Price Associates report in Avidity Biosciences (RNA)?

T. Rowe Price Associates reports beneficial ownership of 142,888 Avidity Biosciences common shares, equal to 0.1% of the class. This reflects a relatively small position and is explicitly described as ownership of 5 percent or less of the outstanding common stock.

How many Avidity Biosciences (RNA) shares can T. Rowe Price vote and dispose of?

T. Rowe Price Associates reports sole voting power over 140,624 shares and sole dispositive power over 142,888 shares of Avidity Biosciences common stock. It reports no shared voting or shared dispositive power over any Avidity Biosciences shares.

What type of SEC filing did T. Rowe Price submit for Avidity Biosciences (RNA)?

T. Rowe Price Associates submitted a Schedule 13G/A (Amendment No. 8) related to Avidity Biosciences common stock. A Schedule 13G is a beneficial ownership report used for investors holding shares without seeking to change or influence the issuer’s control.

As of what date is T. Rowe Price’s Avidity Biosciences (RNA) ownership reported?

The ownership information is reported as of the date of event of 12/31/2025. That date is identified as the event requiring the filing, and the share and percentage figures relate to Avidity Biosciences’ common stock on that date.

Is T. Rowe Price seeking to influence control of Avidity Biosciences (RNA)?

T. Rowe Price Associates certifies the Avidity Biosciences shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control, nor in connection with any transaction having that control-related purpose or effect.

Does T. Rowe Price claim beneficial ownership of the Avidity Biosciences (RNA) shares?

T. Rowe Price Associates states that the filing should not be construed as an admission that it is the beneficial owner of the securities referenced and expressly denies such beneficial ownership, even while reporting the shares for Schedule 13G purposes.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/17/2026 - 10:26 AM Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 8)

AVIDITY BIOSCIENCES INC

(Name of Issuer)

COMMON STOCK

(Title of Class of Securities)

05370A108

(CUSIP Number)

12/31/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 05370A108

1

Names of Reporting Persons

T. Rowe Price Associates, Inc.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

MARYLAND

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 140,624.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 142,888.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

142,888.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

0.1 %

12

Type of Reporting Person (See Instructions)

IA

SCHEDULE 13G

Item 1.
(a)	Name of issuer: AVIDITY BIOSCIENCES INC
(b)	Address of issuer's principal executive offices: 10975 N. TORREY PINES RD., #150, LA JOLLA, CA, 92037
Item 2.
(a)	Name of person filing: T. Rowe Price Associates, Inc.
(b)	Address or principal business office or, if none, residence: 1307 Point Street, Baltimore, MD 21231
(c)	Citizenship: Maryland
(d)	Title of class of securities: COMMON STOCK
(e)	CUSIP No.: 05370A108
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 142888
(b)	Percent of class: 0.1 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 140624
	(ii) Shared power to vote or to direct the vote: 0
	(iii) Sole power to dispose or to direct the disposition of: 142888
	(iv) Shared power to dispose or to direct the disposition of: 0
Item 5.	Ownership of 5 Percent or Less of a Class.
	Ownership of 5 percent or less of a class
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. T. Rowe Price Associates, Inc. hereby declares and affirms that the filing of Schedule 13G shall not be construed as an admission that Price Associates is the beneficial owner of the securities referred to, which beneficial ownership is expressly denied.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

T. Rowe Price Associates, Inc.

Signature:	Ellen York
Name/Title:	Vice President
Date:	02/17/2026